Cited by 160Ovarian cancer diagnosis and treatmentEndometriosis Research and TreatmentEndometrial and Cervical Cancer Treatments

Endometriosis-Associated Ovarian Carcinoma (EAOC): An Entity Distinct from Other Ovarian Carcinomas as Suggested by a Nested Case-Control Study

Eržen, M., Rakar, S., Klančar, B., Syrjänen, K.·2001·Gynecologic Oncology

Abstract

Objectives Endometriosis-associated ovarian carcinoma (EAOC) has recently received increasing attention due to its suggested biological behavior, distinctive from those of usual epithelial ovarian cancer. To elucidate some of the controversies on this intriguing entity, a series of patients with EAOC were compared to ovarian carcinoma cases without concomitant endometriosis.Methods To control the confounding effect of age, a nested case-control study was designed, where all 58 EAOC patients (mean age 54.5 +/- 11.5 years) were nested with four perfectly age-matched non-EAOC patients (n = 232; mean age 54.7 +/- 11.7 years) selected among 425 women representing all FIGO stages of ovarian carcinomas without endometriosis. Pertinent clinical data and results of analysis of the tumors were subjected to statistical analyses using life-table, univariate (Kaplan-Meier), and multivariate (Cox) survival techniques to disclose dissimilarities in the key biological characteristics of these two groups as well as the independent prognostic predictors of disease outcome.Results When compared in a case-control design with four perfectly age-matched non-EAOC patients nested to each EAOC case, the patients with EAOC proved to: (1) have a lower stage disease (both FIGO and TNM) (P = 0.000), (2) show a completely different distribution of histological subtypes (significant overpresentation of endometrioid and clear cell carcinomas) (P = 0.0001), (3) have predominantly lower grade lesions (P = 0.029), (4) be devoid of any primary residual tumor (P = 0.0001), and, most importantly (5) have demonstrated a significantly better overall survival (47/58 versus 126/232; OR 2.89, 95% CI 1.56-5.34, P = 0.0001). This better survival was evident (a) in all age groups and (b) for all histological subtypes, but (c) not explained by a better stage-specific survival in any FIGO stage. The two series also differed in their significant prognostic predictors in Kaplan-Meier and Cox analyses. In the EAOC group, the most significant (P = 0.0001) predictors of OS in univariate analysis were age, histological type, observation time for endometriosis, and distribution of endometriosis. In the non-EAOC group, such significant predictors were age, residual tumor, and type of therapy. In the multivariate (Cox) model, age and FIGO stage were the only two significant independent prognostic factors shared by these two series. In addition, histological type and type of therapy proved to be significant independent predictors in the non-EAOC series.Conclusions These data suggest that EAOC deviates from the non-EAOC in many of its key biological characteristics. The implications of these data in the diagnosis, treatment policy, and prognostication still require confirmation by further studies, however.

Integrity signals

Registry

Crossref · 10.1006/gyno.2001.6382

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Clear cell carcinoma (50% overall survival rate) seems to be more aggressive than endometrioid carcinoma (78% overall survival rate) in malignant ovarian endometriomas.

    “Mainly studied in malignant ovarian endometriomas, clear cell carcinoma (50% overall survival rate) seems to be more aggressive than endometrioid carcinoma (78% overall survival rate) [61].”

The citation lists haven’t been fetched yet

References 40 · Cited by 160

Authors
Eržen, M., Rakar, S., Klančar, B., & Syrjänen, K.
Affiliations
  • Ljubljana University Medical Centre (SI)
  • University of Siena (IT)
Venue
Gynecologic Oncology
Publisher
Elsevier BV
Published
2001-10
Volume
83
Issue
1
Pages
100-108
ISSN
0090-8258 (ISSN-L)
OpenAlex
W2042346163
Cited by
160
References
40
Citations by year
2026: 4 · 2025: 2 · 2024: 4 · 2023: 5 · 2022: 6 · 2021: 4 · 2020: 3 · 2019: 5 · 2018: 8 · 2017: 7 · 2016: 8 · 2015: 13 · 2014: 11 · 2013: 5 · 2012: 14
FWCI
4.29
Type
journal article
Language
en
Open access
closed
Locations
  • Gynecologic Oncology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian cancer diagnosis and treatment
  • Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
  • Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
Keywords
epithelial ovarian cancer, endometriosis, endometrioid carcinoma, clear cell carcinoma, tumor stage, tumor grade, overall survival, prognostic factors, FIGO stage, TNM staging, histological subtypes, age-matched comparison
MeSH terms
Adult, Aged, Aged, 80 and over, Endometriosis, Female, Humans, Middle Aged, Neoplasm Staging, Ovarian Neoplasms, Prognosis, Survival Rate, Case-Control Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review